Rimonabant adds appetizing choice to slim obesity market

  title={Rimonabant adds appetizing choice to slim obesity market},
  author={Meredith Wadman},
  journal={Nature Medicine},
  • Meredith Wadman
  • Published 2006
  • Medicine
  • Nature Medicine
  • If there’s going to be a Prozac of obesity, it might well be rimonabant. A pill that could hit the market as early as spring 2006, rimonabant is being touted as a blockbuster that could net six billion dollars in annual sales by 2010. But the checkered history of diet drugs has some experts worried about the pill’s potential side effects. To fight fat, rimonabant cleverly harnesses the endocannabinoid neurotransmitter system. Activating the endocannabinoid receptor CB1 in the brain gives… CONTINUE READING
    Pharmacological Targeting of Adipocytes/Fat Metabolism for Treatment of Obesity and Diabetes
    • 29
    • PDF
    Recent Developments in the Treatment of Diabetes Type 2
    • 1